Close Menu
October 21, 2019

Broad Genomic Testing for Oncology Clinical Trials and Clinical Practice

Genome Webinar

Head of Medical Genomics,
Glasgow Precision Oncology Laboratory

Genomics is a key element in the potential of precision medicine to transform oncology. Hybrid-capture based targeted next-gen sequencing (NGS) represents a particularly promising option for cancer genomic testing, as it enables the profiling of all cancer-relevant events with the advantage of being compatible with formalin-fixed, paraffin-embedded (FFPE) tissue.

The Glasgow Precision Oncology Laboratory (GPOL) has defined the content required to capture the full range of clinically and biologically important genomic events that characterize solid tumors and turned these into a range of SureSelect cancer NGS assays, the first of which, dubbed Cancer Core, will be presented during this webinar.

In this webinar, Dr. Cooke, head of Medical Genomics of the GPOL shares:

  • How the GPOL has built affordable, fit-for-purpose, cancer NGS solutions using the SureSelect target enrichment platform, specifically to address the challenges of real-world oncology.
  • How the GPOL is implementing broad genomic testing as part of its mission to accelerate the translation of novel cancer therapeutics from discovery to clinical applications.

 For Research Use Only. Not for use in diagnostic procedures.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.